Drug intelligence / Profile preview

DWC202201

Development stage: Phase 2
Lead developer: Daewoong Pharmaceutical

Overview

DWC202201 is an investigational drug currently being studied in phase 1 clinical trials to evaluate its pharmacokinetics, particularly in combination with the proton pump inhibitor DWP14012. The available data indicate that it is being tested for drug-drug interaction potential and safety in healthy adult volunteers. The specific mechanism of action, therapeutic class, molecular structure, and primary indication of DWC202201 have not been disclosed in public sources as of June 2025. The trial sponsor is Daewoong Pharmaceutical.

Beyond the preview

Go deeper on DWC202201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202201.

Explore the full profile